Systemic inflammation during midlife and cognitive change over 20 years: The ARIC Study

Neurology

Volumn 92, Issue 11, 2019, Pages E1256-E1267

  Walker, Keenan A ^a   Gottesman, Rebecca F ^a   Wu, Aozhou ^a   Knopman, David S ^b   Gross, Alden L ^a   Mosley, Thomas H ^c   Selvin, Elizabeth ^a   Windham, B Gwen ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; FIBRINOGEN; VON WILLEBRAND FACTOR;

ADULT; ADULTHOOD; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ASSESSMENT; COGNITION; COGNITIVE AGING; COGNITIVE DEFECT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EXECUTIVE FUNCTION; FEMALE; HUMAN; LANGUAGE; LEUKOCYTE COUNT; MALE; MEMORY ASSESSMENT; MEMORY DISORDER; NERVOUS SYSTEM INFLAMMATION; NEUROPSYCHOLOGICAL TEST; PATHOGENICITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYSTEMIC DISEASE; BLOOD; INFLAMMATION; LONGITUDINAL STUDY; MEMORY; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; COGNITION; COGNITIVE DYSFUNCTION; COHORT STUDIES; EXECUTIVE FUNCTION; FACTOR VIII; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; LANGUAGE; LEUKOCYTE COUNT; LONGITUDINAL STUDIES; MALE; MEMORY; MIDDLE AGED; VON WILLEBRAND FACTOR;

EID: 85062875457     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000007094     Document Type: Article

References (32)

1. Cunningham C, Hennessy E. Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimers Res Ther 2015;7:33.
2. Singh-Manoux A, Dugravot A, Brunner E, et al. Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Neurology 2014;83:486-493.
3. Yaffe K, Kanaya A, Lindquist K, et al. Themetabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-2242.
4. Bialystok E, Craik FIM. Lifespan Cognition: Mechanisms of Change. Oxford, UK: Oxford University Press; 2012.
5. Salthouse TA. Continuity of cognitive change across adulthood. Psychon Bull Rev 2016;23:932-939.
6. Varma VR, Varma S, An Y, et al. Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. Mol Psychiatry 2017;22:13-23.
7. Schmidt MF, Freeman KB, Windham BG, et al. Associations between serum inflammatory markers and hippocampal volume in a community sample. J Am Geriatr Soc 2016;64:1823-1829.
8. Walker KA, Power MC, Hoogeveen RC, et al. Midlife systemic inflammation, late-life white matter integrity, and cerebral small vessel disease. Stroke 2017;48:3196-3202.
9. Walker KA, Hoogeveen RC, Folsom AR, et al. Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC Study. Neurology 2017;89: 2262-2270.
10. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687-702.
11. Papp AC, Hatzakis H, Bracey A,Wu KK. ARIC hemostasis study-I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989;61:15-19.
12. Walker KA, Walston J, Gottesman RF, Kucharska-Newton A, Palta P, Windham BG. Midlife systemic inflammation is associated with frailty in later life: the ARIC Study. J Gerontol A Biol Sci Med Sci Epub 2018 Mar 9.
13. Parrinello CM, Grams ME, Couper D, et al. Recalibration of blood analytes over 25 years in the Atherosclerosis Risk in Communities Study: impact of recalibration on chronic kidney disease prevalence and incidence. Clin Chem 2015; 61:938-947.
14. Schneider ALC, Sharrett AR, Gottesman RF, et al. Normative data for 8 neuropsychological tests in older blacks and whites from the Atherosclerosis Risk in Communities (ARIC) Study. Alzheimer Dis Assoc Disord 2015;29:32-44.
15. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983;29:1075-1080.
16. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28: 1379-1388.
17. Michaud DS, Lu J, Peacock-Villada AY, et al. Periodontal disease assessed using clinical dental measurements and cancer risk in the ARIC Study. J Natl Cancer Inst 2018;110:843-854.
18. Salthouse TA. Continuity of cognitive change across adulthood. Psychon Bull Rev 2016;23:932-939.
19. Rawlings AM, Sharrett AR, Schneider ALC, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 2014;161:785-793.
20. Power MC, Rawlings A, Sharrett AR, et al. Association of midlife lipids with 20-year cognitive change: a cohort study. Alzheimers Dement 2017;14:167-177.
21. Gottesman RF, Schneider ALC, Albert M, et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities neurocognitive study. JAMA Neurol 2014;71:1218-1227.
22. Metti AL, Yaffe K, Boudreau RM, et al. Trajectories of inflammatory markers and cognitive decline over 10 years. Neurobiol Aging 2014;35:2785-2790.
23. Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002;59: 371-378.
24. Laurin D, David Curb J, Masaki KH, White LR, Launer LJ. Midlife C-reactive protein and risk of cognitive decline: a 31-year follow-up. Neurobiol Aging 2009;30: 1724-1727.
25. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168-174.
26. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid ? deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357-367.
27. Dickens AM, Tovar-y-Romo LB, Yoo SW, et al. Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions. Sci Signal 2017;10:eaai7696.
28. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against ?-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol 2009;65:24-31.
29. Moore KJ, El Khoury J, Medeiros LA, et al. A CD36-initiated signaling cascade mediates inflammatory effects of ?-amyloid. J Biol Chem 2002;277:47373-47379.
30. Chavan SS, Huerta PT, Robbiati S, et al. HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med 2012;18:930-937.
31. Carret-Rebillat AS, Pace C, Gourmaud S, et al. Neuroinflammation and A? accumulation linked to systemic inflammation are decreased by genetic PKR down-regulation. Sci Rep 2015;5:8489.
32. Thayer JF, Sternberg EM. Neural aspects of immunomodulation: focus on the vagus nerve. Brain Behav Immun 2010;24:1223-1228.